Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2015-05-13 Regulatory Filings
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Adaptimmune Therapeutics plc, pursuant to SEC rules. It contains announcements of press releases about management appointment and presentation of data at a conference, but does not include any financial statements or detailed financial data. The document length is short (2390 characters) and it mainly reports other events and press releases. It does not contain an annual report, interim report, earnings release, or other detailed financial or governance reports. It is a regulatory filing reporting other events and press releases, which fits best under the Regulatory Filings (RNS) category as a fallback for miscellaneous filings that do not fit other categories.
2015-05-13 English
13G PIG
Major Shareholding Notification
2015-05-11 English
Regulatory Filings 2015
Regulatory Filings
2015-05-07 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC. Form S-8 is used for registering securities to be offered to employees under employee benefit plans, such as share option schemes. The text includes detailed information about share option plans, registration fees, indemnification of directors and officers, and incorporation by reference of other filings. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2015-05-07 English
424B4
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) of Adaptimmune Therapeutics plc, including information about the offering price, underwriting, risk factors, financial information, management discussion, and corporate reorganization. It is filed pursuant to rule 424(b)(4), which is a prospectus filing related to securities offerings. The document contains extensive financial and business information but is not an annual report, earnings release, or other financial report type. It is a registration/prospectus document related to capital raising and securities issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a full prospectus related to financing.
2015-05-07 English
Regulatory Filings 2015
Regulatory Filings
2015-05-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.